SCHEMBL1018374

SCHEMBL1018374

Cc1nc(N2CCOCC2)nc2c1CN(CC(=O)N1CCN(C3CCC3)CC1)CC2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 1/20 0.47
PIK3CA P42336 6/20 0.38
HRH3 Q9Y5N1 5/20 0.38
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 1/20 0.35
PIK3R1 P27986 4/20 0.35
ADRA1A P35348 1/20 0.35
GBA1 P04062 1/20 0.35
MTOR P42345 1/20 0.34
PIK3CG P48736 1/20 0.34
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017235 0.81 HSP90AB1 (0.47) ALDH1A1KDM4EHRH3ADRA1ASMN1; SMN2
SCHEMBL1014897 0.80 HSP90AB1 (0.47) ALDH1A1KDM4EPIK3CAADRA1ASMN1; SMN2
SCHEMBL1020740 0.77 KDM4E (0.42) ALDH1A1KDM4EHRH3ALOX15TSHR
SCHEMBL1020109 0.77 KDM4E (0.41) ALDH1A1KDM4EHRH3ALOX15TSHR
SCHEMBL1018360 0.77 KDM4E (0.46) ALDH1A1KDM4EHPGDHRH3ALOX15
SCHEMBL967841 0.74 KDM4E (0.39) ALDH1A1KDM4EPIK3CAHRH3PARP1
SCHEMBL970335 0.74 MCHR1 (0.42) ALDH1A1KDM4EPIK3CAHRH3PARP1
SCHEMBL1018741 0.73 HSP90AB1 (0.47) ALDH1A1SMN1; SMN2
SCHEMBL1016546 0.73 HSP90AA1 (0.44)
SCHEMBL1017394 0.73 KDM4E (0.41) ALDH1A1KDM4EHPGDHRH3ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ALDH1A1 1229/4885KDM4E 2634/4885HPGD 725/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 1229/4885KDM4E 2634/4885HPGD 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.